News

Minovia Therapeutics Ltd. a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline

Celltrion has received approval from the U.S. Food and Drug Administration (FDA) for EYDENZELT® (aflibercept-boav), a biosimilar referencing EYLEA® (aflibercept). 

Vivace Therapeutics, Inc., a biotechnology company focused on developing small molecule cancer therapies that target the Hippo pathway, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA)

Made Scientific, a leading clinical and commercial-enabling cell therapy contract development and manufacturing organization (CDMO), and Streamline Bio, a next-generation autonomous robotics company solving critical challenges

AbbVie today announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois.

Cellectar Biosciences, Inc. a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Evestia Clinical (“Evestia”), a leading independent global specialist Contract Research Organization (CRO), have entered into an agreement whereby

Merck, a leading science and technology company, and Siemens, a leading technology company, signed a new Memorandum of Understanding (MoU), extending their strategic partnership to accelerate digital transformation in the life science industry

Starpharma an innovative Australian biotechnology company, today announced the signing of a collaboration and license agreement with Genentech, a member of the Roche Group, to develop potential cancer therapies that leverage Starpharma’s proprietary DEP® drug delivery technology.

Minovia Therapeutics Ltd. a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration

VarmX, a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has entered into a strategic collaboration with global biotechnology leader,